According to Zhitong Finance App, Tiger Pharmaceuticals (03347.HK) announced 2026 interim results, with revenue of 3,707.76 billion yuan, up 14.1% year on year; gross profit of about 1,021 billion yuan, up 4.3% year on year; net loss due to company owners about 413 million yuan, year-on-year profit from profit and loss due to shareholders of listed companies excluding non-recurring profit and loss was about 278 million yuan, an increase of 31.8% year on year; loss per share was 0.48 yuan.

According to Zhitong Finance App, Tiger Pharmaceuticals (03347.HK) announced 2026 interim results, with revenue of 3,707.76 billion yuan, up 14.1% year on year; gross profit of about 1,021 billion yuan, up 4.3% year on year; net loss due to company owners about 413 million yuan, year-on-year profit from profit and loss due to shareholders of listed companies excluding non-recurring profit and loss was about 278 million yuan, an increase of 31.8% year on year; loss per share was 0.48 yuan.